ClinicalTrials.gg
CompletedNCT03814200Updated Jul 3, 2025

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

A Phase 1 interventional study of Saline and ACT-246475 in Healthy Subject, sponsored by Viatris Innovation GmbH. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study will investigate the effect of rifampicin on the uptake and breakdown of ACT-246475 in healthy subjects

02

Conditions studied

  • Healthy Subject
03

In context

Lead sponsor

Viatris Innovation GmbH is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the subject prior to any study-mandated procedure
  • Healthy male and female subjects aged between 18 and 65 years (inclusive) at Screening
  • of 18.0 to 30.0 kg/m2 (inclusive) at Screening
  • Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 45-90 bpm (inclusive), measured on the same arm, after 5 min in the supine position at screening and on Day -1 of the first period
  • Hematology and coagulation test results not deviating from the normal range to a extent at Screening and on Day -1 of the first period
  • Women of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day- 1 of the first treatment period and must agree to consistently and correctly use a highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to ACT-246475.
  • Previous exposure to rifampicin within 3 months prior to Screening.
  • Known to P2Y12 receptor antagonists or rifampicin, or to any of the rifamycins, or any of their
  • Loss of 250 mL or more of blood within 3 months prior to Screening
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
  • Family or personal history of prolonged bleeding (e.g., after surgical intervention) or bleeding disorders (e.g., thrombocytopenia, clotting disturbances), intracranial vascular diseases, stroke, reasonable suspicion of vascular malformations, or peptic ulcers
  • Known disorders (e.g., Glanzmann thromboasthenia, von Willebrand disease, platelet release defect)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Treatment period A

    Treatment A1: saline 0.9% followed by Treatment A2: ACT-246475

    Drug: Saline · Drug: ACT-246475

  • Experimental
    Treatment period B

    Treatment B1: rifampicin followed by Treatment B2: ACT-246475

    Drug: ACT-246475 · Drug: Rifampicin

Interventions

  • DrugSaline

    Single i.v. infusion of 100 mL saline 0.9% for 30 min

  • Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions

    Also known as: Selatogrel

  • Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t)

    The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to 36 hours after treatment administration

  2. AUC from zero to infinity (AUC0-inf)

    The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to 36 hours after treatment administration

  3. The maximum plasma concentration (Cmax)

    The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to 36 hours after treatment administration

  4. The time to reach Cmax (tmax)

    The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to 36 hours after treatment administration

  5. Terminal half-life (t½)

    The plasma PK parameters of ACT-246475 will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to 36 hours after treatment administration

07

Study locations

1 site
  • QPS Netherlands B.V.
    Groningen, 9700, Netherlands
08

References and documents

Publications

  • Schilling U, Dingemanse J, Voors-Pette C, Romeijn C, Dogterom P, Ufer M. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel. Clin Transl Sci. 2020 Sep;13(5):886-890. doi: 10.1111/cts.12774. Epub 2020 Mar 31. PubMed 32166864 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Feb 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2019
First posted
Jan 23, 2019
StartActual
Jan 3, 2019
Primary completionActual
Feb 12, 2019
CompletionActual
Feb 19, 2019
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03814200
Responsible party
Sponsor
First posted
Jan 23, 2019
Start date
Jan 3, 2019
Primary completion
Feb 12, 2019
Completion
Feb 19, 2019
Last update
Jul 3, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selatogrel

Start the discussion